Savara Inc (SVRA) stock
Close on Nov 13, 2026Market cap $953.33MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $953.33M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 8.84
- Dividend yield
- –
- Free cash flow yield
- -13.74%
Fundamentals
- Net income
- -$152.74M
- EPS, diluted
- -$0.61
- Free cash flow
- -$130.95M
- Book value per share
- $0.42
- Diluted shares
- 254M
Trading
- Previous close
- $4.72
- Open
- $4.80
- Day's range
- $4.58 – $4.84
- Volume
- 3,231,792
- Average volume (20 days)
- 2,954,701
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 1.01
- 52-week range
- $4.03 – $7.00
- RSI (14 days)
- 45.9
- Volatility (1 year)
- 54.9%
- Relative volume
- 1.55×
- WACC
- 10.0%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | SVRA | S&P 500 | Difference | SVRA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.9% | -3.0% | +0.1 pts | ||
| 3 months | -12.0% | -2.8% | −9.2 pts | ||
| Year to date | -23.1% | +11.5% | −34.5 pts | ||
| 1 year | +8.9% | +13.5% | −4.5 pts | ||
| 3 years | +34.1% | +77.7% | −43.6 pts | +10.3% | +21.1% |
| 5 years | +310.6% | +72.6% | +238.0 pts | +32.6% | +11.5% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Savara filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- Update
- Update
- Update
- News
About Savara
Pharmaceutical Preparations
Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company's sole program is molgramostim inhalation solution, an investigational biologic consisting of inhaled granulocyte-macrophage colony-stimulating factor. It is being developed specifically to treat autoimmune pulmonary alveolar proteinosis, a rare condition that causes surfactant accumulation within the lungs' air sacs. Molgramostim delivers the therapeutic formulation using an exclusive, proprietary nebulizer system, with patients afflicted by this rare autoimmune condition serving as its primary target population.
Company profile, executives and historySavara stock: common questions
What is Savara's stock price?
SVRA closed at $4.64 on Nov 13, 2026, down 1.69% on the day. Over the past 52 weeks it traded between $4.03 and $7.00.
What is Savara's market cap?
Savara was worth $953.33M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is SVRA's P/E ratio?
Savara lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.61), so it has no meaningful P/E ratio.
Does Savara pay a dividend?
No. Savara has not paid a cash dividend over the last twelve months.
How has SVRA stock performed over the past year?
Including dividends, SVRA returned +8.9% over the past year, against +13.5% for the S&P 500.
How many SVRA shares are sold short?
32M shares were sold short at the latest FINRA report, 20.66% of the float, or 12.9 days of average trading volume.
Who are Savara's competitors?
Companies most similar to Savara by business, industry and size include GOSS, GRI, CNTB, INSM, VERA.
See a number that looks wrong?